RELIEF THERAPEUTICS HLDG - RLFTF STOCK NEWS

NeuroRx announced positive interim results for ZYESAMI™ (aviptadil) in a Phase 2b/3 trial for treating respiratory failure in critically ill Covid-19 patients. The drug showed a 35% higher likelihood of recovery by day 28 compared to placebo, with a median 10-day acceleration in recovery time. As High Flow Nasal Oxygen becomes the main treatment for such patients, NeuroRx plans to apply for Emergency Use Authorization if positive trends continue. The trial involved 10 U.S. hospitals and is part of a collaboration with RELIEF THERAPEUTICS. NeuroRx is also completing a business combination with Big Rock Partners Acquisition Corporation (BRPA).

On February 9, 2021, NeuroRx and Relief Therapeutics announced preliminary results from the Phase 2b/3 trial of ZYESAMI™ in COVID-19 patients experiencing respiratory failure. The trial indicated significant improvements for patients receiving ZYESAMI compared to those on placebo, including earlier hospital discharge and reduced ICU time. The data suggests a potential Emergency Use Authorization submission for ZYESAMI, indicating its importance as the first drug specifically targeting critically ill COVID-19 patients. However, primary endpoint results are still pending.

Relief Therapeutics Holding AG announced the immediate resignation of board member Thomaz Burckhardt, who is stepping down to focus on other professional interests. Chairman Raghuram Selvaraju expressed gratitude for Burckhardt's contributions. The company is seeking candidates to fill the vacancy with individuals who have substantial experience in life sciences and healthcare. Relief continues to prioritize its clinical-stage programs, notably RLF-100^TM, currently being tested for respiratory issues related to COVID-19.

Relief Therapeutics announced the initiation of a phase 2/3 trial for inhaled RLF-100(TM) to treat severe COVID-19 patients, in collaboration with UCI Health. The trial aims to determine if RLF-100(TM) can prevent progression to critical illness. Additionally, top-line data from a previous phase 2b/3 trial of intravenous RLF-100(TM) is expected to be released this month after ongoing statistical analyses. Relief's focus is on developing treatments for respiratory diseases based on clinically tested molecules.

Relief Therapeutics is holding an Extraordinary General Meeting (EGM) for shareholders on December 17, 2020, due to COVID-19 restrictions. Shareholders registered by December 4, 2020, can vote through an independent proxy. Key agenda items include the election of Tom Plitz to the Board of Directors, compensation adjustments for the Board and Executive Committee, and increases in authorized and conditional share capital. These changes aim to enhance the company's flexibility for future financing and development of its lead compound, RLF-100^TM, targeting severe COVID-19 cases.

Relief Therapeutics, in collaboration with NeuroRx, has enrolled 150 patients in a phase 2b/3 trial for RLF-100(TM), targeting respiratory failure in critical COVID-19 cases. The trial aims to assess the drug's effectiveness, with no serious adverse events reported thus far. An earlier study indicated a significant survival advantage linked to RLF-100(TM). Additionally, main shareholder GEM has exercised 500 million warrants, increasing Relief's cash balance to approximately CHF 49.8 million.

Relief Therapeutics Holding AG announced the appointment of Dr. J. Paul Waymack as a development and regulatory consultant to bolster its management team, focusing on the late-stage development of RLF-100^TM for severe COVID-19 patients. Dr. Waymack brings extensive experience in drug development, having previously led Kitov Pharmaceuticals and served in various roles at the U.S. FDA. Relief is currently advancing RLF-100^TM through Phase 2b/3 trials, aiming to offer new therapeutic options for COVID-19, with FDA Emergency Use Authorization granted to treat respiratory failure.

Relief Therapeutics has appointed Jack Weinstein as Chief Financial Officer (CFO) and Treasurer, effective immediately. Weinstein, with over 40 years of experience in biopharmaceutical finance and investment banking, will manage investor engagement and financial strategies. Raghuram Selvaraju, Chairman, expressed confidence in Weinstein's ability to support the company during the crucial development of its lead compound, RLF-100^TM, aimed at treating severe COVID-19 patients. Jeremy Meinen has been promoted to Vice President of Finance and Administration, while Yves Sagot transitions to a consulting role.